Chloe Sligar

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 13

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Monoclonal Antibody

Top Venues

International journal of molecular sciences

Clinical & translational immunology

Immunology and cell biology

Bioscience reports

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Chloe Sligar, Ellie Reilly, Peter Cuthbertson, Kara Lea Vine, Katrina M Bird, Amal Elhage, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice. Clinical & translational immunology 13 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Chloe Sligar, Ellie Reilly, Peter Cuthbertson, Kara Lea Vine, Katrina M Bird, Amal Elhage, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice. Clinical & translational immunology 13 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Amal Elhage, Peter Cuthbertson, Chloe Sligar, Debbie Watson, Ronald Sluyter
A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice. Pharmaceutics 15 (9) (2023)
Chloe Sligar, Peter Cuthbertson, Nicole A Miles, Sam R Adhikary, Amal Elhage, Geoff Zhang, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide. Immunology and cell biology (2023)
Chloe Sligar, Peter Cuthbertson, Nicole A Miles, Sam R Adhikary, Amal Elhage, Geoff Zhang, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide. Immunology and cell biology (2023)
Amal Elhage, Chloe Sligar, Peter Cuthbertson, Debbie Watson, Ronald Sluyter
Insights into mechanisms of graft-versus-host disease through humanised mouse models. Bioscience reports 42 (9) (2022)
Debbie Watson, Sam R Adhikary, Peter Cuthbertson, Nicholas J Geraghty, Katrina M Bird, Amal Elhage, Chloe Sligar, Ronald Sluyter
Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease. Methods in molecular biology (Clifton, N.J.) 2510 (2022)
Sam R Adhikary, Peter Cuthbertson, Leigh Nicholson, Katrina M Bird, Chloe Sligar, Min Hu, Philip J O'Connell, Ronald Sluyter, Stephen I Alexander, Debbie Watson
Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model. Immunology 164 (2) (2021)